▼ -100.00% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Relx in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $25.88.
The current consensus among 10 investment analysts is to buy stock in Relx. This rating has held steady since January 2020, when it changed from a Hold consensus rating.
RELX PLC provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics that help institutions and professionals to progress in science and advance healthcare. The Risk & Business Analytics segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk. The Legal segment provides legal, regulatory, and business information and analytics that help customers in decision-making, as well as enhance the productivity. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier PLC and changed its name to RELX PLC in July 2015. RELX PLC was incorporated in 1903 and is headquartered in London, the United Kingdom.